AGTC to Present at Upcoming Conferences
December 05 2016 - 7:00AM
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced its participation in upcoming
conferences.
- Genetic Rx — Boston, Mass. (December 8, 2016)
AGTC President & CEO Sue Washer will be moderating a panel
discussion entitled “Manufacturing and Commercialization:
Strategies for Success” from 11:45am – 12:15pm ET. The event
will take place at Harvard Medical School and will bring together
academics, key industry leaders and investors to discuss the
emergence of new genetic medicines as well as the treatment of
patients with rare genetic diseases.
- BMO Capital Markets Prescriptions for Success
Healthcare Conference – New York, N.Y. (December 14,
2016)Sue Washer will provide a company presentation at
3:20pm ET. Ms. Washer will discuss key corporate milestones in
addition to reviewing AGTC's clinical pipeline. A live audio
webcast of the presentation can be accessible by visiting
ir.agtc.com/events.cfm. A replay will be available on the company’s
website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its
proprietary gene therapy platform to develop products designed to
transform the lives of patients with severe diseases, with an
initial focus in ophthalmology. AGTC's lead product candidates are
designed to treat inherited orphan diseases of the eye, caused by
mutations in single genes that significantly affect visual function
and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology
development programs across five targets (X-linked retinoschisis
(XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet
age-related macular degeneration and blue cone monochromacy), two
non-ophthalmology programs (alpha-1 antitrypsin deficiency and
adrenoleukodystrophy) and AGTC is continuing to develop early
research studies in additional indications. The company is also
exploring genetic defects in cells in the inner ear that lead to
deafness and expects to advance several product candidates into
development within the next few years. AGTC employs a highly
targeted approach to selecting and designing its product
candidates, choosing to develop therapies for indications having
high unmet medical need, clinical feasibility and commercial
potential. AGTC has a significant intellectual property portfolio
and extensive expertise in the design of gene therapy products
including capsids, promoters and expression cassettes, as well as,
expertise in the formulation, manufacture and physical delivery of
gene therapy products.
IR/PR CONTACTS:
David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
dcarey@lazarpartners.com or dlewis@lazarpartners.com
Corporate Contacts:
Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
lbullock@agtc.com
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024